Sri Lanka’s imports of pharmaceuticals from India are facing critical regulatory and pricing bottlenecks, causing friction between Indian suppliers and Sri Lankan authorities.
The Island Nation depends on India for approximately 30% to 85% of its total medicine requirements. However, a major standoff over price controls and licensing delays has severely strained the supply chain
The Indian High Commission has formally intervened with Sri Lankan authorities, advocating for the streamlined clearance of the stalled licenses to safeguard bilateral medical trade.
Despite private-sector bottlenecks, the state sector continues to award vital contracts directly to top-tier Indian companies, such as the government contract awarded to Reliance Life Sciences for critical autoimmune medications
Over 1,000 import license applications from Indian firms are stalled at the National Medicines Regulatory Authority (NMRA). The NMRA is pressing for lower Maximum Retail Prices (MRP), which Indian suppliers argue ignores logistics and currency factors.
Severe delays in clearance have depleted three-month buffer stocks for many essential branded medicines. To avert shortages, the government is considering a 6-7% price increase for imports.
The Indian High Commission has intervened, warning of market withdrawal by suppliers due to these bottlenecks.
Following discussions with the suppliers, the Indian High Commission raised the matter with the Sri Lankan authorities,
The import of branded medicines from Indian companies to Sri Lanka is currently navigating an acute supply chain crisis caused by regulatory backlogs and pricing disputes.
Sri Lanka relies heavily on India, which provides 70% to 85% of its total pharmaceutical imports. However, a tense standoff between Indian manufacturers and Sri Lankan authorities has put the continuity of certain branded supplies at immediate risk
More than 1,000 import license applications and renewals submitted by reputable Indian pharmaceutical firms have been stuck pending approval at the National Medicines Regulatory Authority (NMRA).
Applications have faced processing delays, creating significant friction for companies attempting to clear shipments at ports.
The NMRA has been aggressively pressuring Indian suppliers to reduce their Maximum Retail Prices (MRP).
This demand extends even to specialized branded medicines that are completely excluded from Sri Lanka’s official price-control list.
Indian firms argue that these forced price drops are commercially unviable because they fail to account for rising raw materials, global logistics, and shipping costs.
While the NMRA uses a fixed monthly exchange rate matrix to approve prices setting the benchmark at LKR 333.12 per USD.
Manufacturers state that currency fluctuations and the overall depreciation of the Sri Lankan Rupee over the broader timeline have significantly inflated their actual import costs.
Suppliers argue that the regulator’s pricing model fails to dynamically absorb these macroeconomic shifts.
Unable to cope with ad-hoc pricing and regulatory gridlocks, several top-tier global multinationals have already exited or scaled back operations. High-reputation Indian pharmaceutical firms are now following suit by reducing their market presence and hesitating to register new branded products.
Medical entities have warned that this friction has depleted safety buffers, risking shortages of specialized branded products.
To prevent an absolute breakdown of the healthcare supply chain, the government has shown a recent willingness to compromise..
The Ministry of Health is actively reviewing requests from the Sri Lanka Chamber of Pharmaceutical Importers to grant an approximate 7% price hike on essential items to cushion suppliers against operational losses.